Research Article

Helicobacter pylori Infection Is Associated with an Increased Risk of Hyperemesis Gravidarum: A Meta-Analysis

Lin Li,1,2 Lingling Li,2,3 Xiaoying Zhou,1,2 Shuping Xiao,1,2 Huiyuan Gu,1,2 and Guoxin Zhang1,2

1Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
2First Clinical Medical College, Nanjing Medical University, Nanjing 210029, China
3Department of Respiratory Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Correspondence should be addressed to Guoxin Zhang; guoxinz@njmu.edu.cn

Received 16 December 2014; Revised 13 February 2015; Accepted 22 February 2015

Academic Editor: Haruhiko Sugimura

Copyright © 2015 Lin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Several studies have shown a possible involvement of Helicobacter pylori (H. pylori) infection in individuals with hyperemesis gravidarum (HG), but the relationship remains controversial. This meta-analysis was performed to validate and strengthen the association between HG and H. pylori infection.

Methods. PubMed, Embase, and Web of Science databases up to March 20, 2014, were searched to select studies on the prevalence of H. pylori infection between pregnant women with HG and the normal pregnant control subjects.

Results. Of the HG cases, 1289 (69.6%) were H. pylori-positive; however, 1045 (46.2%) were H.pylori-positive in control group. Compared to the non-HG normal pregnant controls, infection rate of H. pylori was significantly higher in pregnant women with HG (OR = 3.34, 95% CI: 2.32–4.81, \( P < 0.001 \)). Subgroup analysis indicated that H. pylori infection was a risk factor of HG in Asia, Africa, and Oceania, especially in Africa (OR = 12.38, 95% CI: 7.12–21.54, \( P < 0.001 \)).

Conclusions. H.pylori should be considered one of the risk factors of HG, especially in the developing countries. H.pylori eradication could be considered to relieve the symptoms of HG in some intractable cases.

1. Introduction

Hyperemesis gravidarum (HG), the most severe form of pregnancy-associated nausea and vomiting, is leading to weight loss, nutritional deficiencies, and metabolic disturbance, for example, dehydration, acidosis from starvation, hypokalemia, and transient hepatic dysfunction, often requiring hospitalization and medical treatment to avoid life-threatening complications [1]. HG complicates 0.3–2% of all pregnancies and is a multifactorial disease; however, little is known about the etiology of HG. But a variety of mechanisms may play a role in this disease, such as endocrine factors like human chorionic gonadotropin (HCG), estradiol, and progesterone and immunologic factors, as well as personal factors in which increased body weight has been proposed as possible underlying cause [2]. Recently, several studies have put emphasis on the correlation between Helicobacter pylori (H. pylori) infection and the risk of HG [3–6].

H. pylori, as a gram-negative flagellated spiral bacterium, colonizes stomach and creates the basis of pathogenesis of gastric pathologies, including chronic gastritis, duodenal and gastric ulcers, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma [7–9]. H. pylori infected the stomach of 50% of the world population, and it is more prevalent in developing countries [10]. The prevalence of H. pylori infection in pregnant women varies according to socioeconomic conditions, geographic area, and even the method used to test H. pylori infection.

Several studies have shown a possible involvement of H. pylori infection in individuals with HG; however, other studies did not share with them. Although three previous meta-analyses have shown the positive association between H. pylori and HG, the role of H. pylori infection in the pathogenesis of HG has not reached a consensus. Moreover, the previous meta-analyses did not use the comprehensive search method, unable to include the overall studies, and
2. Materials and Methods

2.1. Data Sources. We systematically identified studies in PubMed, Embase, and Web of Science (inception through March 20, 2014) databases by two independent investigators (LL and LLL) for all relevant literatures between the risk of HG and the infection of *H. pylori*, by using the MeSH terms, “Helicobacter pylori” OR “*H. pylori*” OR “Helicobacter infection” AND “hyperemesis gravidarum.” These were searched both as thesaurus terms and as text words. Even “nausea and vomiting” as text word was searched too. Finally, a Google Scholar search was done. Moreover, the references at the end of selected papers were also examined for additional relevant studies.

2.2. Inclusion Criteria. In our meta-analysis, the included articles had to meet the following criteria: (1) they must be case-control studies or prospective studies or cross-sectional studies; (2) studies must refer to the association of *H. pylori* infection with HG risk and must provide raw data on *H. pylori* infection in both HG and control groups; (3) the participants must have had a clinical diagnosis of hyperemesis gravidarum as follows: pernicious vomiting, weight loss, and at least one positive ketonuria; (4) the confirmation of *H. pylori* infection was detected by enzyme-linked immunosorbent assay (ELISA), stool antigen test, ^13^C-urea breath test (^13^C-UBT), mucosal biopsy, and polymerase chain reaction (PCR). At least one positive result was considered as confirmation of infection.

2.3. Exclusion Criteria. We excluded studies as follows: (1) reports without control groups; (2) reviews and duplicated publications; (3) studies in which the source of *H. pylori* infection in cases and control subjects and other essential information were not offered; hyperthyroidism, multiple gestation trophoblastic neoplasia, gastrointestinal and hepatic disorders, urinary tract or other infections, psychosocial or any other maternal disorders, and any treatment with antacids or antibiotics within the previous 7 days were excluded as well.

2.4. Data Extraction. According to the inclusion criteria, data was carefully extracted independently by two reviewers (LL and LLL). For each study analyzed, we collected data including first author, year of publication, country of the population studied, study design, sources of pregnant women (primipara or multipara), gestational age, diagnosis of hyperemesis gravidarum, methods of *H. pylori* detection, total number of persons in cases and controls, and the numbers of *H. pylori*-positive and *H. pylori*-negative patients in the HG group and the control group of each study which were recorded, respectively. For conflicting evaluations, an agreement was reached by consensus and agreement with another reviewer (XYZ), referring back to the original articles.

2.5. Statistical Analysis. We used pooled odds ratio (OR) with its corresponding 95% confidence interval (CI) to estimate the strength of the association between HG and *H. pylori* infection. Post hoc subgroup analyses were also performed to explain the heterogeneity in results. Subgroups were explored as follows: detection of *H. pylori* infection (serum *H. pylori* IgG/IgM/IgA antibody by ELISA, stool antigen test, mucosal biopsy from endoscopy, or *H. pylori* genome by PCR), publication period (1996–2000, 2001–2005, 2006–2010, or 2011–2014), and region (Asia, North America, Europe, Africa, or Oceania).

The heterogeneity of the studies included in this meta-analysis was assessed using the Q statistic test and the I^2^ statistic test. The random-effects model was selected when P value < 0.1 or I^2^ > 50%; otherwise, the fixed-effects model was selected. Possible publication bias was evaluated by visual inspection of funnel plots and application of Begg’s and Egger’s test [11–15]. P values of less than 0.05 from Egger’s test were considered statistically significant.

All statistical analyses were done with STATA statistical software package version 12.0 (2000; STATA Corp., College Station, TX, USA); P < 0.05 was identified as statistically significant.

3. Results

3.1. Literature Search. As shown in Figure 1, after rigorous searching, we identified 104 citations. Of these, fifty-six irrelevant papers were excluded after screening the titles. In the remaining 48 articles, 16 studies included five studies without control group, two did not provide sufficient data, and 9 reviews or meta-analyses were discarded. Thus, a total of thirty-two studies included twenty-nine case-control studies and three cross-sectional studies published between 1998 and 2014 fulfilled our inclusion criteria and were included in the meta-analysis [3–6, 16–43].

3.2. Characteristics of Included Studies. With respect to the *H. pylori* detection methods, serum *H. pylori* IgG/IgM/IgA antibody was detected by ELISA in twenty-nine, one, and one studies, respectively. However, *H. pylori* stool antigen (HpSA) was used in seven articles, *H. pylori* genome by PCR (Hp PCR DNA) tested in two studies, and biopsy and histological examination from endoscopy in one literature. Taking into account publication period, five studies were published from 1996 to 2000, twelve researches were from 2001 to 2005, eight studies were from 2006 to 2010, and seven articles were from 2011 to 2014. In addition, in terms of region, twenty studies were from Asian countries (Turkey, Iran, Japan, and China were grouped in Asia according to similarities in geographic position and racial traits), five from North America (USA, Canada, and Puerto Rico were grouped in North America according to similarities in geographic location and racial
indicated that there was a powerful association between founding factors that may have impacted the overall results. To evaluate the underlying con-

3.4. Subgroup Analysis. To evaluate the underlying confounding factors that may have impacted the overall results, we further conducted subgroup analyses based on detection of H. pylori infection, publication period, and region, respectively. Since \( I^2 \) were 0 in subgroups of Hp PCR DNA test and Africa, we selected the fixed-effects model. In the remaining subgroups, \( I^2 \) were >50\%, so the random-effects models were used. As shown in Table 3, ORs of serum H. pylori IgM/IgA antibody test by ELISA were 7.77 (95% CI: 0.43–140.84) and 1.32 (95% CI: 0.56–3.12), respectively, which suggested that there was no association between H. pylori and HG. However, serum H. pylori IgG antibody test by ELISA (OR = 3.32, 95% CI: 2.28–4.84), HpSA test (OR = 1.88, 95% CI: 1.33–2.65), and Hp PCR DNA test (OR = 5.87, 95% CI: 2.47–13.93) reflected H. pylori infection was a risk factor of HG. In addition, method of histological examination from endoscopy also showed a positive correlation between H. pylori infection and HG (OR = 19.0, 95% CI: 1.79–201.68). With respect to publication period, studies from 1996 to 2000 (OR = 3.66, 95% CI: 1.17–11.48), 2001 to 2005 (OR = 3.89, 95% CI: 2.10–7.21), 2006 to 2010 (OR = 2.01, 95% CI: 1.15–3.49), and 2011 to 2014 (OR = 4.41, 95% CI: 1.72–11.29) all showed significantly high rates of H. pylori infection in pregnant women with HG compared to those with normal pregnancy (Table 3). In the subgroup of region, shown in Table 3, compared to those studies in North America (OR = 2.33, 95% CI: 0.63–8.62) and Europe (OR = 1.55, 95% CI: 0.83–2.91), researches of Asia (OR = 3.27, 95% CI: 2.18–4.91), Africa (OR = 12.38, 95% CI: 7.12–21.54), and Oceania (OR = 10.93, 95% CI: 5.22–22.85) reflected H. pylori was positively related to HG.

3.5. Bias Diagnostics. Begg’s test was created for assessment of possible publication bias (Figure 3). The \( P \) values for Egger’s tests were \( P = 0.067 \) \((P > 0.05)\), indicating the absence of heterogeneity and implying that the results of the present meta-analysis were relatively stable and that the publication bias might exert little influence on the overall results.

4. Discussion

4.1. Main Findings. This updated meta-analysis suggests that exposure to H. pylori is associated with an increased risk of HG. The studies included in this meta-analysis, containing 1851 HG patients of which 1289 cases were confirmed with H. pylori infection, implied that the rate of H. pylori infection was much greater in HG patients (1289/1851) than that in non-HG patients (1045/2262) after adjusting for confounding variables \((P < 0.001)\).

Our meta-analysis contained 32 articles including 29 case-control studies and 3 cross-sectional articles, which contained comprehensive articles and added new primary studies. We enrolled much more patients with HG (1851) and controls (2262) than those in published studies to further confirm this relationship. We separated subgroups in detection of H. pylori infection, publication period, and region to comprehensively evaluate the underlying confounding factors that may have impacted the overall results. As reported before, three previous articles reported similar meta-analysis results [44–46]. Golberg et al. [44] performed a meta-analysis of 14 studies and did subgroup analysis only...
| First author, year | Study design | Country   | Sample size | HG definition                        | Detection method of *H. pylori* | Gestational age when included in the study | Sources of pregnant women |
|-------------------|-------------|-----------|-------------|--------------------------------------|---------------------------------|------------------------------------------|--------------------------|
| Frigo, 1998 [16]  | Case-control | Austria   | 234         | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum IgG antibodies by FEI     | —                                        | —                        |
| Perez-Perez, 1999 [18] | Case-control | USA       | 89          | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum cagA by ELISA             | —                                        | —                        |
| Ko´cak, 1999 [17] | Case-control | Turkey    | 211         | Vomiting >3 times/day ketonuria        | Serum IgG antibodies by FEI     | 7–16 weeks                              | 141 Primigravida 70 Multigravida |
| Hayakawa, 2000 [19] | Case-control | Japan     | 63          | Nausea and vomiting in first trimester | Serum IgG antibodies by ELISA   | The first trimester                       | —                        |
| Sahin, 2000 [20]  | Case-control | Turkey    | 120         | Prolonged severe vomiting dehydration weight loss >5% ketonuria | Serum IgG antibodies by ELISA   | —                                        | —                        |
| Reymunde, 2001 [21] | Case-control | Puerto Rico | 89     | Daily nausea and vomiting in gestation weeks 6–16 | Serum IgG antibodies not specified | 6–16 weeks                              | —                        |
| Kazerooni, 2002 [24] | Case-control | Iran      | 107         | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum IgG antibodies by ELISA   | 7–16 weeks                              | 62 Primigravida 45 Multigravida |
| Bagis, 2002 [23]  | Case-control | Turkey    | 30          | Severe HG in the first 16 weeks of pregnancy | Endoscopy with biopsy + histological examination | 16 weeks                                | —                        |
| Erdem, 2002 [22]  | Case-control | Turkey    | 86          | Vomiting >4 times/day weight loss >5% ketonuria | Serum IgG antibodies by ELISA   | —                                        | —                        |
| Berker, 2003 [27]  | Case-control | Turkey    | 240         | Vomiting >3 times/day weight loss >5% ketonuria | Serum IgG antibodies by ELISA   | 10–14 weeks                             | 55 Primigravida 105 Multigravida |
| Jacobson, 2003 [26] | Case-control | Canada    | 206         | Vomiting >3 times/day weight loss ketonuria | Serum IgG antibodies by ELISA   | 7–19 weeks                              | —                        |
| Salimi-Khayati, 2003 [25] | Case-control | Iran      | 108         | Vomiting >3 times/day weight loss >5% ketonuria | Serum IgG antibodies by ELISA   | 6–16 weeks                              | 93 Primigravida 15 Multigravida |
| Karaca, 2004 [31]  | Case-control | Turkey    | 146         | Vomiting >3 times/day weight loss >5% ketonuria | Serum IgG antibodies by FEI     | —                                        | —                        |
| Cevrioglu, 2004 [30] | Case-control | Turkey    | 124         | Vomiting >3 times/day weight loss >5% ketonuria | Serum IgG antibodies by ELISA   | The first 16 weeks                       | —                        |
| Xia, 2004 [29]    | Case-control | China     | 172         | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum specific IgG antibodies and CagA by ELISA | 7–16 weeks                             | 172 Multigravida          |
| First author, year | Study design | Country | Sample size | HG definition | Detection method of *H. pylori* | Gestational age when included in the study | Sources of pregnant women |
|-------------------|-------------|---------|-------------|---------------|----------------------------------|----------------------------------------|--------------------------|
| Jamal, 2004 [28]  | Case-control | Iran    | 94          | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum IgG antibodies by ELISA          | 7–16 weeks                            | 49 Primigravida 45 Multigravida |
| Lee, 2005 [32]    | Cross-sectional | USA    | 82          | Vomiting >3 times/day weight loss >5% ketonuria | Serum IgG antibodies by ELISA          | —                                      | —                        |
| Karadeniz, 2006 [34] | Case-control | Turkey | 60          | Vomiting >3 times/day weight loss >5% ketonuria | Serum IgG antibodies by ELISA          | 8–14 weeks                            | —                        |
| Özçimen, 2006 [33] | Cross-sectional | Turkey | 140         | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum IgG antibodies by ELISA          | —                                      | —                        |
| Tuncel, 2006 [35] | Case-control | Turkey | 138         | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum IgG antibodies by ELISA          | —                                      | —                        |
| Hatziveis, 2007 [38] | Case-control | Greece | 110         | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum IgG antibodies by ELISA          | 8–14 weeks                            | 39 Primigravida 71 Multigravida |
| Güney, 2007 [37]  | Case-control | Turkey | 60          | Vomiting >4 times/day weight loss >5% ketonuria | Serum IgG antibodies not specified     | 7–12 weeks                            | —                        |
| Aytac, 2007 [36]  | Case-control | Turkey | 107         | Vomiting >3 times/day weight loss >5% ketonuria | Stool antigen by ELISA                 | 8–13 weeks                            | —                        |
| Sandven, 2008 [39] | Case-control | Norway | 488         | ICD-9 Code 643.1 | Serum IgG antibodies by EIA        | —                                      | —                        |
| Mansour, 2009 [40] | Case-control | Egypt  | 100         | Vomiting >3 times/day weight loss ketonuria     | Serum IgG antibodies by ELISA          | 10–16 weeks                            | 67 Primigravida 33 Multigravida |
| Guven, 2011 [5]   | Cross-sectional | Turkey | 80          | Vomiting >3 times/day weight loss >5% ketonuria dehydration | Serum IgG antibodies by ELISA          | 7–12 weeks                            | —                        |
| Mansour, 2011 [4]  | Case-control | Egypt  | 160         | Vomiting >3 times/day weight loss >3 kg ketonuria | Serum IgG antibodies by ELISA          | 10–16 weeks                            | —                        |
| Bezircioğlu, 2011 [3] | Case-control | Turkey | 72          | Vomiting >4 times/day weight loss ≥3 kg ketonuria | Stool antigen by ELISA                 | 10–14 weeks                            | —                        |
| Epstein, 2012 [41]| Case-control | USA    | 82          | Met the diagnosis of hyperemesis               | Serum IgG antibodies by ELISA          | —                                      | —                        |
| First author, year | Study design | Country  | Sample size | HG definition                                | Detection method of *H. pylori* | Gestational age when included in the study | Sources of pregnant women |
|-------------------|--------------|----------|-------------|---------------------------------------------|---------------------------------|--------------------------------------------|--------------------------|
| Vikanes, 2013 [43] | Case-control | Norway   | 170         | Long-lasting nausea and vomiting, weight loss, electrolyte disturbances | Serum IgG antibodies and CagA and VacA by EIA | 17th and 22nd                               | —                        |
| Güngören, 2013 [42] | Case-control | Turkey   | 140         | Vomiting 3 times/day weight loss ketone     | Serum IgG antibodies by ELISA   | Below the 20th week                         | —                        |
| Shaban, 2014 [6] | Case-control | Egypt    | 100         | Vomiting >3 times/day weight loss >5% or 3 kg ketonuria | Serum IgG antibodies by membrane-based immunoassay | 5–12 weeks                                 | 36 Primigravida 64 Multigravida |

HP: *Helicobacter pylori*; HG: hyperemesis gravidarum; FEI: fluorescent enzyme immunoassay; EIA: enzyme immunoassay; ELISA: enzyme-linked immunosorbent assay.
| Study ID                          | OR (95% CI)          | Weight (%) |
|----------------------------------|----------------------|------------|
| Frigo et al. (1998)              | 10.93 (5.22, 22.85)  | 3.51       |
| Perez-Perez et al. (1999)        | 0.69 (0.25, 1.89)    | 3.11       |
| Koçak et al. (1999)              | 13.38 (5.95, 30.13)  | 3.40       |
| Hayakawa et al. (2000)           | 4.31 (1.40, 13.25)   | 2.95       |
| Sahin (2000)                     | 1.41 (0.68, 2.91)    | 3.52       |
| Reymunde et al. (2001)           | 109.33 (24.49, 488.12)| 2.42       |
| Kazerooni et al. (2002)          | 3.64 (1.52, 8.73)    | 3.31       |
| Bagis et al. (2002)              | 19.00 (1.79, 201.68) | 1.50       |
| Erdem et al. (2002)              | 3.20 (1.14, 9.02)    | 3.08       |
| Berker et al. (2003)             | 1.48 (0.77, 2.85)    | 3.62       |
| Jacobson et al. (2003)           | 1.34 (0.69, 2.60)    | 3.61       |
| Salimi-Khayat et al. (2003)      | 11.64 (4.25, 31.87)  | 3.12       |
| Karaca et al. (2004)             | 2.54 (1.13, 5.70)    | 3.41       |
| Cevrioglu et al. (2004)          | 2.11 (0.66, 6.67)    | 2.90       |
| Xia et al. (2004)                | 9.78 (4.25, 22.51)   | 3.37       |
| Jamal et al. (2004)              | 2.78 (1.18, 6.54)    | 3.34       |
| Lee et al. (2005)                | 0.93 (0.37, 2.31)    | 3.26       |
| Karadeniz et al. (2006)          | 0.55 (0.17, 1.77)    | 2.87       |
| Özcimen et al. (2006)            | 1.12 (0.58, 2.18)    | 3.61       |
| Tuncel et al. (2006)             | 4.93 (1.08, 22.54)   | 2.39       |
| Hatziveis et al. (2007)          | 1.37 (0.56, 3.35)    | 3.28       |
| Güney et al. (2007)              | 4.00 (1.07, 14.90)   | 2.67       |
| Aytac et al. (2007)              | 1.10 (0.51, 2.38)    | 3.46       |
| Sandven et al. (2008)            | 2.42 (1.64, 3.57)    | 3.92       |
| Mansour and Nashaat (2009)       | 9.33 (3.60, 24.17)   | 3.20       |
| Guven et al. (2011)              | 7.43 (2.70, 20.42)   | 3.11       |
| Mansour (2011)                   | 18.41 (7.93, 42.74)  | 3.36       |
| Beziroglu et al. (2011)          | 10.00 (1.18, 84.78)  | 1.70       |
| Epstein et al. (2012)            | 1.26 (0.45, 3.56)    | 3.08       |
| Vikanes et al. (2013)            | 0.97 (0.51, 1.84)    | 3.63       |
| Güngören et al. (2013)           | 3.33 (1.51, 7.36)    | 3.43       |
| Shaban et al. (2014)             | 9.04 (2.82, 28.95)   | 2.89       |
| Overall (I² = 81.5%, P = 0.000)  | 3.34 (2.32, 4.81)    | 100.00     |

Note: weights are from random-effects analysis

Figure 2: Meta-analysis for the association between HG and Helicobacter pylori infection.

Figure 3: Publication bias tests for the overall data (H. pylori-positive versus H. pylori-negative).
Table 2: Statistical analysis of studies on the rate of *H. pylori* infection in HG cases and non-HG controls.

| First author, year | Number of cases | Number of controls | Number of cases with HP (+), n (%) | Number of controls with HP (+), n (%) | OR (95% CI) |
|--------------------|-----------------|--------------------|-----------------------------------|--------------------------------------|-------------|
| Frigo, 1998 [16]   | 105             | 129                | 95 (90.5)                         | 60 (46.5)                            | 10.93 (5.22, 22.85) |
| Perez-Perez, 1999 [18] | 42              | 47                 | 8 (19.1)                          | 12 (25.5)                            | 0.69 (0.25, 1.89)   |
| Koçak, 1999 [17]   | 95              | 116                | 87 (91.5)                         | 52 (44.8)                            | 13.38 (5.95, 30.13) |
| Hayakawa, 2000 [19] | 34              | 29                 | 18 (52.9)                         | 6 (20.6)                             | 4.31 (1.40, 13.25)  |
| Sahin, 2000 [20]   | 60              | 60                 | 37 (61.7)                         | 32 (53.3)                            | 1.41 (0.68, 2.91)   |
| Reymunde, 2001 [21] | 45              | 44                 | 40 (89.0)                         | 3 (7.0)                              | 109.33 (24.49, 488.12) |
| Kazerooni, 2002 [24] | 54              | 53                 | 44 (81.5)                         | 29 (54.7)                            | 3.64 (1.52, 8.73)   |
| Bagis, 2002 [23]   | 20              | 10                 | 19 (95.0)                         | 5 (50.0)                             | 19.00 (1.79, 201.68) |
| Erdem, 2002 [22]   | 47              | 39                 | 40 (85.1)                         | 25 (64.1)                            | 3.20 (1.14, 9.02)   |
| Berker, 2003 [27]  | 80              | 80                 | 56 (70.0)                         | 49 (61.2)                            | 1.48 (0.77, 2.85)   |
| Jacobson, 2003 [26] | 39              | 55                 | 26 (66.7)                         | 23 (41.8)                            | 2.78 (1.18, 6.54)   |
| Salimi-Khayati, 2003 [25] | 54          | 54                 | 48 (88.9)                         | 22 (40.7)                            | 11.64 (4.25, 31.87) |
| Karaca, 2004 [31]  | 56              | 90                 | 46 (82.1)                         | 58 (64.4)                            | 2.54 (1.13, 5.70)   |
| Cevrioglu, 2004 [30] | 27              | 97                 | 23 (85.2)                         | 71 (73.2)                            | 2.11 (0.66, 6.67)   |
| Xia, 2004 [29]     | 72              | 100                | 64 (88.9)                         | 45 (45.0)                            | 9.78 (4.25, 22.51)  |
| Jamal, 2004 [28]   | 39              | 55                 | 26 (66.7)                         | 23 (41.8)                            | 2.78 (1.18, 6.54)   |
| Lee, 2005 [32]     | 40              | 42                 | 26 (65.0)                         | 28 (66.7)                            | 0.93 (0.37, 2.31)   |
| Karadeniz, 2006 [34] | 31              | 29                 | 21 (67.7)                         | 23 (79.3)                            | 0.55 (0.17, 1.77)   |
| Özçimen, 2006 [33] | 70              | 70                 | 35 (50.0)                         | 33 (47.1)                            | 1.12 (0.58, 2.18)   |
| Tuncel, 2006 [35]  | 50              | 88                 | 48 (96.0)                         | 73 (82.9)                            | 4.93 (1.08, 22.54)  |
| Hatziveis, 2007 [38] | 25              | 85                 | 14 (56.0)                         | 41 (48.2)                            | 1.37 (0.56, 3.35)   |
| Güney, 2007 [37]   | 25              | 20                 | 20 (80.0)                         | 10 (50.0)                            | 4.00 (1.07, 14.90)  |
| Aytac, 2007 [36]   | 52              | 55                 | 22 (42.3)                         | 22 (40.0)                            | 1.10 (0.51, 2.38)   |
| Sandven, 2008 [39] | 244             | 244                | 105 (43.0)                        | 58 (23.8)                            | 2.42 (1.64, 3.57)   |
| Mansour, 2009 [40] | 50              | 50                 | 42 (84.0)                         | 18 (36.0)                            | 9.33 (3.60, 24.17)  |
| Guven, 2011 [5]    | 40              | 40                 | 32 (80.0)                         | 14 (35.0)                            | 7.43 (2.70, 20.42)  |
| Mansour, 2011 [4]  | 80              | 80                 | 71 (88.8)                         | 24 (30.0)                            | 18.41 (793, 42.74)  |
| Bezircioğlu, 2011 [3] | 36          | 36                 | 8 (22.2)                          | 1 (2.8)                              | 10.00 (1.18, 84.78) |
| Epstein, 2012 [41] | 23              | 59                 | 16 (69.6)                         | 58 (38.0)                            | 1.26 (0.45, 3.56)   |
| Vikanes, 2013 [43] | 62              | 108                | 38 (61.3)                         | 67 (62.0)                            | 0.97 (0.51, 1.84)   |
| Güngören, 2013 [42] | 90              | 50                 | 75 (83.3)                         | 30 (60.0)                            | 3.33 (1.51, 7.36)   |
| Shaban, 2014 [6]   | 50              | 50                 | 46 (92.0)                         | 28 (56.0)                            | 9.04 (2.82, 28.95)  |

HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval.

on markers of *H. pylori* infection, which suggested that the association might be possible if testing methods for active *H. pylori* infection used nonserological methods. However, our meta-analysis showed that the serological method such as *H. pylori* IgG antibody test was relatively credible. Sandven et al. [45] included 25 case-control studies containing 1455 HG and 1970 controls and carried out subgroups analyses on matched design with nonmatched design and Turkish population with other population. We separated subgroup analyses of region according to Asia, North America, Europe, Africa, or Oceania as described above. Niemeijer et al. [46] performed a systematic review to summarize evidence on biomarkers of HG and their value in diagnosis and estimating disease severity and carried out a diagnostic meta-analysis of 19 studies on *H. pylori* IgG, which showed a sensitivity of 73% and a specificity of 55% in the diagnosis of HG as compared to controls without HG. Our study paid attention not only to the detection method of *H. pylori* IgG, but also to the methods of Hp PCR DNA and HpSA. We also described other detection methods used in pregnant women.

With respect to detection methods used in pregnant women, Hp PCR DNA test seemed much more efficient than ELISA test of serum *H. pylori* IgG antibody, and the latter was more reliable than HpSA test. Of note, Cevrioglu et al. [30] collected both serum and feces samples from pregnant women with HG to investigate specific antibodies for *H. pylori* (immunoglobulin-IgG, IgA) and HpSA, and only HpSA test suggested significant association between *H. pylori* infection and HG while serologic assessment failed to reflect the association (40% versus 12.4%, *P* < 0.001). By using PCR
with specimen of saliva, Günsören et al. [42] found a positive relationship between the symptoms of HG and *H. pylori* positivity, while test of *H. pylori* IgG/IgM antibody failed to detect this association between the symptoms of HG and *H. pylori* positivity. From biopsies of the gastric antrum and corpus, Bagis et al. [23] found that, compared to controls, HG patients were detected with higher *H. pylori* density, degree of inflammation, and *H. pylori* activation, implying that *H. pylori* density might be related to HG since the bacterium density of controls was lower. These results suggested that the degree of gastric complaints might be related to density of *H. pylori*.

In addition, two studies from New Zealand indicate that incidence of hyperemesis gravidarum differs according to women’s ethnic origin [47, 48]. Just as shown in our subgroup analysis of region, studies in North America and Europe suggested no association between *H. pylori* infection and risk of HG, while in Asia, Africa, and Oceania analysis indicated *H. pylori* infection was a risk factor of HG, especially in Africa. Sandven et al. [39] also found this association between *H. pylori* infection and HG was much stronger in Africans as compared to non-Africans. This might be explained by ethnicity and low socioeconomic status. *H. pylori*-infected Africans possibly carry an aggressive variant of the bacterium and the host immune mechanisms might be a key to different responses to *H. pylori* in different populations and geographic areas. As well documented, the prevalence rate of *H. pylori* infection is much higher in developing countries than that in developed countries [49–51]. As Eshraghian reviewed, the overall prevalence of *H. pylori* infection in Iran and other Eastern Mediterranean Regional Office countries such as Egypt and Afghanistan, irrespective of time and age group, ranged from 30.6% to 82% and ranged from 22% to 87.6%, respectively. However the *H. pylori* prevalence in North Africa was 76% [52]. The prevalence is high in developing countries, while pregnant women with HG in these countries have higher rate of *H. pylori* infection. For example, it is 50%–70% in Turkey [53], more than 80% in Egypt [54]. The above studies all suggested that *H. pylori* infection was a risk factor of HG. Strategies to improve sanitary facilities, educational status, and socioeconomic status should be implemented to minimize *H. pylori* infection and come into the result of decline prevalence of HG.

Our meta-analysis suggested that *H. pylori* infection was a risk factor of HG. Frigo et al. suggested that the *H. pylori* may contribute to its persistence beyond the normal time course [16]. It was once reported that HG was an oxidative stress condition induced by increasing reactive oxygen species (ROS) activity and decreasing antioxidant status [55]. Meanwhile, *H. pylori* colonizes gastric mucosa and generates ROS as well as downregulating levels of plasma antioxidants such as ascorbic acid [7], similar to Güney et al. [37] who found that, compared to the control, level of serum malondialdehyde (MDA) was significantly higher and activities of antioxidant enzymes such as superoxide dismutase (SOD), catalase (CT), and glutathione peroxidase (GSH-Px) were significantly lower in *H. pylori*-infected pregnant women with HG in these countries, while pregnant women with HG in the above studies all suggested that *H. pylori* infection was a risk factor of HG. Strategies to improve sanitary facilities, educational status, and socioeconomic status should be implemented to minimize *H. pylori* infection and come into the result of decline prevalence of HG.

| Subgroup | Number of studies | Cases with HP (+) | Controls with HP (+) | OR [95% CI] | P | Z | Tests of heterogeneity |
|----------|------------------|------------------|---------------------|--------------|---|---|-----------------------|
| Region   |                  |                  |                     |              |   |   |                       |
| Asia     | 20               | 769/1017         | 593/1121            | 3.27 [2.18, 4.91] | <0.001 | 5.71 | 68.04 | 19 <0.001 72.1 |
| North America | 5             | 109/203          | 28/345              | 2.33 [0.63, 8.62] | 0.205 | 1.27 | 36.55 | 4 <0.001 89.1 |
| Europe   | 3                | 157/331          | 166/437             | 1.55 [0.83, 2.91] | 0.170 | 1.37 | 6.18 2 0.046 67.6 |
| Africa   | 3                | 159/180          | 70/180              | 12.38 [7.12, 21.54] | <0.001 | 8.91 | 1.47 2 0.479 0 |
| Oceania  | 1                | 95/105           | 60/129              | 3.34 [2.32, 4.81] | <0.001 | 6.35 | 0.00 0 — — |
| Year     |                  |                  |                     |              |   |   |                       |
| 1996–2000| 5                | 245/336          | 162/381             | 3.66 [1.17, 11.48] | 0.026 | 2.23 | 35.41 | 4 <0.001 88.7 |
| 2001–2005| 12               | 451/587          | 403/817             | 3.89 [2.10, 7.21] | <0.001 | 4.32 | 57.01 11 <0.001 80.7 |
| 2006–2010| 8                | 307/547          | 278/641             | 2.01 [1.15, 3.49] | 0.014 | 2.47 | 24.07 7 0.001 70.9 |
| 2011–2014| 7                | 286/381          | 202/423             | 4.41 [1.72, 11.29] | 0.002 | 3.09 | 39.71 6 <0.001 84.9 |
| HP testing method | |                  |                     |              |   |   |                       |
| HplgGAb  | 29               | 1240/1743        | 1017/2161           | 3.32 [2.28, 4.84] | <0.001 | 6.25 | 158.05 28 <0.001 82.3 |
| HpSA     | 7                | 124/300          | 124/435             | 1.88 [1.33, 2.65] | 0.0004 | 3.57 | 9.50 6 0.091 47.4 |
| HpDNA PCR| 2                | 45/124           | 30/79               | 5.87 [2.47, 13.93] | <0.001 | 4.02 | 0.63 1 0.43 0 |
| HplgAAAb | 1                | 13/27            | 40/97               | 1.32 [0.56, 3.12] | 0.52 | 0.64 | 0.00 0 — — |
| HplgMAAb | 1                | 6/90             | 0/50                | 7.77 [0.43, 140.84] | 0.17 | 1.39 | 0.00 0 — — |
| histologically | 1             | 19/20            | 5/10                | 19.00 [1.79, 201.68] | 0.01 | 2.44 | 0.00 0 — — |
| All studies | 32              | 1289/1851        | 1045/1217           | 3.34 [2.32, 4.81] | <0.001 | 6.51 | 167.81 31 <0.001 81.5 |

HP: *Helicobacter pylori*; HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval; df: degrees of freedom; HplgGAb: *H. pylori* IgG antibodies; HplgAAAb: *H. pylori* IgA antibodies; HplgMAAb: *H. pylori* IgM antibodies; HpSA: *H. pylori* stool antigen; Hp DNA PCR: *H. pylori* genome by PCR.
HG is still very limited, and we assumed the following. Firstly, hormonal mechanisms, in the early phase of pregnancy, as a result of the elevated steroid and human chorionic gonadotropin (HCG) levels, accumulation of fluid, and a displacement of intracellular and extracellular volume occur which in turn leads to a shift in pH in the gastrointestinal tract during pregnancy [40, 56]. Secondly, emotional factors, the moods of pregnant women change frequently due to the changes of endocrine hormones that might increase women's susceptibility to infection caused by altered cell-mediated immunity that causes changes of various classes of antibodies during different gestational periods [57, 58]. Thirdly, H. pylori infection might be one potential reason for HG. Dysmotility of gastrointestinal tract and prolonged gastric emptying and intestinal transit time induced by pregnancy might favor infection of H. pylori [56, 58]. On the other side, host inflammation response to varies of virulence of H. pylori strains also different from each other. The virulence of the organism might be another factor creating a possible link between H. pylori and the precipitation of HG. As we all know, cytotoxin-associated gene A product (CagA) and vacuolating cytotoxin A (VacA) are used as markers for genomic diversity of H. pylori. In Western countries VacA, rather than CagA, was associated with more severe diseases, while in East Asian countries it is the opposite [59–61]. Similarly, as shown in Table 4, Xia et al. in Asia (OR = 13.96, 95% CI: 6.56–29.71) found that prevalence of H. pylori infection with CagA was positively correlated with HG [29]. Nevertheless Perez-Perez et al. in USA [18] failed to find that CagA plays a role in HG. To date, Vikanes et al. [43] conducted the first case-control study to examine the relationship between H. pylori and HG by both CagA and VacA seropositivity in Norway and their results suggested that CagA and VacA seropositivity were not significantly associated with HG. So the role of CagA and VacA in the pathopoiesis of HG was still unclear, and no more studies were performed to explore this relationship. It suggested that study of CagA and VacA might be generalized and probably aim at the populations with high prevalence rate of H. pylori infection.

On the other hand, eradication of H. pylori could relieve the symptoms of HG. Strachan et al. reported a case of eradication in a 38-year-old woman in her third pregnancy, who orally omeprazole 20 mg bid, metronidazole 400 mg bid, and amoxicillin 500 mg tid for 7 days in her 30 weeks of pregnancy. This led to prompt resolution of her vomiting and improvement of her reflux symptoms [62]. El Younis et al. also reported two cases in which first-trimester patients with severe HG required intravenous fluid replacement. Rapid improvement of the HG was observed with complete resolution of all symptomatology after using of erythromycin therapy orally, which possibly suggests a new therapeutic modality for similar patients [63]. On the other hand, omeprazole is not licensed for use in pregnancy and ought to be used with caution although experience from case-control and observational studies has not revealed any increase in congenital malformations or pregnancy complications [64]. Large-scale studies were not performed. However, the above case reports could verify that the eradication of H. pylori might relieve the symptoms of HG.

### Table 4: The infection rate of CagA- or VacA-positive H. pylori in HG cases and controls.

| First author, year | Region | Number of cases | Number of controls | Number of cases with CagA- and/or VacA-positive H. pylori, n  | Number of controls with CagA- and/or VacA-positive H. pylori, n  | OR (95% CI) |
|--------------------|--------|-----------------|--------------------|---------------------------------------------------------------|---------------------------------------------------------------|--------------|
| Xia, 2004 [29]    | Asia   | 72              | 100                | 50 (69.4%)                                                   | 14 (14%)                                                      | 13.96 (6.56, 29.71) |
| Vikanes, 2013 [43]| Europe | 62              | 108                | 21 (33.9%)                                                   | 44 (40.8)                                                      | 0.75 (0.39, 1.43)  |

CagA: cytotoxin-associated gene A product; VacA: vacuolating cytotoxin A; HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval.

4.2. Interpretation. This meta-analysis has some limitations to be acknowledged. Firstly, our meta-analysis only focused on papers published in the English language and might miss some eligible studies that were unpublished in other languages. Secondly, the articles identified were limited to those openly published up to March 2014, and it is possible that some related published or unpublished studies that might meet the inclusion criteria were missed. Finally, despite using a precise literature searching strategy to identify eligible studies, it is possible that a few studies meeting the inclusion criteria were not included, resulting in any inevitable bias, though the funnel plots and Egger’s tests failed to show any significant publication bias.

5. Conclusion

In conclusion, our meta-analysis suggested that there was a strong association between H. pylori infection and HG, allowing us to conclude that H. pylori should, therefore, be considered as one of the risk factors of HG. Screening for H. pylori should be added to the investigations for HG, especially in the developing countries. Appropriate therapeutic regimens for eradication of H. pylori could be considered to relieve the symptoms of HG in some intractable cases.

Conflict of Interests

The authors declare that there is no conflict of interests.

Authors’ Contribution

Lin Li, Lingling Li, and Xiaoying Zhou contributed equally to this paper. Lin Li conceived and designed the paper; Lin Li, Lingling Li, and Shuping Xiao extracted data; Lingling Li and Xiaoying Zhou analyzed the data; Huiyuan Gu...
and Guoxin Zhang contributed materials/analysis tools; Lin Li and Guoxin Zhang contributed to the writing of the manuscript; Guoxin Zhang proofread the paper.

Acknowledgment

The authors would like to thank the authors of the studies that have made up the database for this meta-analysis.

References

[1] S. K. Ismail and L. Kenny, “Review on hyperemesis gravidarum,” Best Practice and Research in Clinical Gastroenterology, vol. 21, no. 5, pp. 755–769, 2007.

[2] M. F. G. Verberg, D. J. Gillott, N. Al-Fardan, and J. G. Grudzinskas, “Hyperemesis gravidarum, a literature review,” Human Reproduction Update, vol. 11, no. 3, pp. 527–539, 2005.

[3] I. Bezircio˘glu, H. B. Elveren, A. Balog˘lu, and M. Biçe¸r, “The positivity of Helicobacter pylori stool antigen in patients with hyperemesis gravidarum,” Journal of the Turkish German Gynecology Association, vol. 12, no. 2, pp. 71–74, 2011.

[4] G. M. Mansour and E. H. Nashaat, “Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum,” Archives of Gynecology and Obstetrics, vol. 284, no. 4, pp. 843–847, 2011.

[5] M. A. Guven, I. E. Ertas, A. Coskun, and P. Cirag˘l, “Serologic and stool antigen assay of Helicobacter pylori infection in hyperemesis gravidarum: Which test is useful during early pregnancy?” Taiwanese Journal of Obstetrics and Gynecology, vol. 50, no. 1, pp. 37–41, 2011.

[6] M. M. Shaban, H. O. Kandil, and A. H. Elshafei, “Helicobacter pylori seropositivity in patients with hyperemesis gravidarum,” The American Journal of the Medical Sciences, vol. 347, no. 2, pp. 101–105, 2014.

[7] M. Gong, S. S. M. Ling, S. Y. Lui, K. G. Yeoh, and B. Ho, “Helicobacter pylori γ-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease,” Gastroenterology, vol. 139, no. 2, pp. 564–573, 2010.

[8] Z. Wang, Y. Yu, W. Yang, B. Chen, and X. Li, “Does Helicobacter pylori eradication really reduce the risk of gastric cancer at the population level?” Gut, vol. 62, no. 6, p. 950, 2013.

[9] S. Nakamura, T. Sugiyama, T. Matsumoto et al., “Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan,” Gut, vol. 61, no. 4, pp. 507–513, 2012.

[10] H. M. Malaty, “Epidemiology of Helicobacter pylori infection,” Best Practice and Research: Clinical Gastroenterology, vol. 21, no. 2, pp. 205–214, 2007.

[11] J. P. T. Higgins, S. G. Thompson, J. I. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003.

[12] N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” Journal of the National Cancer Institute, vol. 22, pp. 719–748, 1959.

[13] R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986.

[14] C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994.

[15] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997.

[16] P. Frigo, C. Lang, K. Reisenberger, H. Köbl, and A. M. Hirschel, “Hyperemesis gravidarum associated with Helicobacter pylori seropositivity,” Obstetrics & Gynecology, vol. 91, no. 4, pp. 615–617, 1998.

[17] I. Koçak, Y. Akcan, C. Üstün, C. Demirel, L. Cengiz, and F. F. Yanik, “Helicobacter pylori seropositivity in patients with hyperemesis gravidarum,” International Journal of Gynecology and Obstetrics, vol. 66, no. 3, pp. 251–254, 1999.

[18] G. I. Perez-Perez, R. M. Peek, A. J. Legath, P. R. Heine, and L. B. Graff, “The role of CagA status in gastric and extragastrointestinal complications of Helicobacter pylori,” Journal of Physiology and Pharmacology, vol. 50, no. 5, pp. 833–845, 1999.

[19] S. Hayakawa, N. Nakajima, M. Karasaki-Suzuki et al., “Frequent presence of Helicobacter pylori genome in the saliva of patients with hyperemesis gravidarum,” The American Journal of Perinatology, vol. 17, no. 5, pp. 243–248, 2000.

[20] H. G. Sahin, H. A. Sahin, K. Onbası, and I. Sahin, “Hyperemesis and Helicobacter pylori,” Nagoya Medical Journal, vol. 44, no. 65–72, 2000.

[21] A. Reymunde, N. Santiago, and L. Perez, “Helicobacter pylori and severe morning sickness,” The American Journal of Gastroenterology, vol. 96, no. 7, pp. 2279–2280, 2001.

[22] A. Erdem, M. Arslan, M. Erdem, G. Yildirim, and O. Himmeto˘glu, “Detection of Helicobacter pylori seropositivity in hyperemesis gravidarum and correlation with symptoms,” American Journal of Perinatology, vol. 19, no. 2, pp. 87–92, 2002.

[23] T. Bagis, Y. Gumurdulu, F. Kayaselcuk, E. S. Yilmaz, E. Killic-cadag, and E. Tarim, “Endoscopy in hyperemesis gravidarum and Helicobacter pylori infection,” International Journal of Gynecology and Obstetrics, vol. 79, no. 2, pp. 105–109, 2002.

[24] T. Kazeroomi, M. Taalomon, and A. A. Ghaderi, “Helicobacter pylori seropositivity in patients with hyperemesis gravidarum,” International Journal of Gynecology and Obstetrics, vol. 79, no. 3, pp. 217–220, 2002.

[25] A. Salimi-Khayati, H. Sharami, F. Mansour-Ghanaei, S. Sadri, and M.-S. Fallah, “Helicobacter pylori seropositivity and the incidence of hyperemesis gravidarum,” Medical Science Monitor, vol. 9, no. 1, pp. CR12–CR15, 2003.

[26] G. F. Jacobson, A. M. Autry, T. L. Somer-Shely, K. L. Pieper, and R. S. Kirby, “Helicobacter pylori seropositivity and hyperemesis gravidarum,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 48, no. 8, pp. 578–582, 2003.

[27] B. Berker, S. Soydemir, S. D. Cengiz, and S. K. Kose, “Serologic assay of Helicobacter pylori infection: is it useful in hyperemesis gravidarum?” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 48, no. 10, pp. 809–812, 2003.

[28] A. Jamal, P. Poorsanari, and R. Ansari, “Relationship between Helicobacter pylori seropositivity and hyperemesis gravidarum,” Acta Medica Iranica, vol. 42, pp. 367–370, 2004.

[29] L.-B. Xia, J. Yang, A.-B. Li, S.-H. Tang, Q.-Z. Xie, and D. Cheng, “Relationship between hyperemesis gravidarum and Helicobacter pylori seropositivity,” Chinese Medical Journal, vol. 117, no. 2, pp. 301–302, 2004.

[30] A. S. Cevriog˘lu, M. Altindis, M. Yilmazer, J. V. Fencki, E. Ellidokuz, and S. Kose, “Efficient and non-invasive method for investigating Helicobacter pylori in gravida with hyperemesis gravidarum: Helicobacter pylori stool antigen test,” Journal of Obstetrics and Gynaecology Research, vol. 30, no. 2, pp. 136–141, 2004.

[31] Ç. Karaca, N. Gülner, A. Yazar, H. Çamlica, K. Demir, and G. Yildirim, “Is lower socio-economic status a risk factor for Helicobacter pylori infection in pregnant women with hyperemesis...
gravidarum?" *Turkish Journal of Gastroenterology*, vol. 15, no. 2, pp. 86–89, 2004.

[32] R. H. Lee, V. L. Pan, and D. A. Wing, "The prevalence of *Helicobacter pylori* in the Hispanic population affected by hyperemesis gravidarum," *The American Journal of Obstetrics and Gynecology*, vol. 193, no. 3, pp. 1024–1027, 2005.

[33] E. E. Ozcimen, A. Uckuyu, I. Üstüner, F. F. Yanik, S. Kulaksizoglu, and M. Öktem, "*Helicobacter pylori* positivity in patients with hyperemesis gravidarum," *Obstetrics, Gynaecology & Reproductive Medicine*, vol. 12, pp. 165–168, 2006.

[34] R. S. Karadeniz, O. Ozdegirmenci, M. M. Altay et al., "*Helicobacter pylori* seropositivity and stool antigen in patients with hyperemesis gravidarum," *Infectious Diseases in Obstetrics and Gynecology*, vol. 2006, Article ID 73073, 3 pages, 2006.

[35] T. Tuncel, G. Köse, N. Aka, and P. Kumru, "The role of *Helicobacter pylori* in hyperemesis gravidarum," *Obstetrics, Gynaecology & Reproductive Medicine*, vol. 12, pp. 100–102, 2006.

[36] S. Aytaç, C. Türkyay, and M. Kanbay, "*Helicobacter pylori* stool antigen assay in hyperemesis gravidarum: a risk factor for hyperemesis gravidarum or not?" *Digestive Diseases and Sciences*, vol. 52, no. 10, pp. 2840–2843, 2007.

[37] M. Güney, B. Oral, and T. Mungan, "Serum lipid peroxidation and antioxidant potential levels in hyperemesis gravidarum," *American Journal of Perinatology*, vol. 24, no. 5, pp. 283–289, 2007.

[38] K. Hatziveis, D. Tournakis, P. Hountis et al., "Relationship between *Helicobacter pylori* seropositivity and hyperemesis gravidarum with the use of questionnaire," *Minerva Ginecologica*, vol. 59, no. 6, pp. 579–583, 2007.

[39] I. Sandven, M. Abdelnoor, M. Wethe et al., "*Helicobacter pylori* infection and Hyperemesis gravidarum. An institution-based case-control study," *European Journal of Epidemiology*, vol. 23, no. 7, pp. 491–498, 2008.

[40] G. M. Mansour and E. H. Nashaat, "*Helicobacter pylori* and hyperemesis gravidarum," *International Journal of Gynecology and Obstetrics*, vol. 106, no. 1, pp. 63–64, 2009.

[41] A. Epstein, D. A. Wing, J. G. Ouzounian, D. A. Miller, and R. H. Lee, "*Helicobacter pylori* and thrombocytopenia in the pregnant Hispanic population," *Journal of Maternal-Fetal and Neonatal Medicine*, vol. 25, no. 12, pp. 2588–2590, 2012.

[42] A. Güngören, N. Bayramoğlu, N. Duran, and M. Kurul, "Association of *Helicobacter pylori* positivity with the symptoms in patients with hyperemesis gravidarum," *Archives of Gynecology and Obstetrics*, vol. 288, no. 6, pp. 1279–1283, 2013.

[43] Å. V. Vikanes, N. C. Steer, N. Gunnes et al., "*Helicobacter pylori* infection and severe hyperemesis gravidarum among immigrant women in Norway: a case-control study," *European Journal of Obstetrics Gynecology and Reproductive Biology*, vol. 167, no. 1, pp. 41–46, 2013.

[44] D. Golberg, A. Szilagyi, and L. Graves, "Hyperemesis gravidarum and *Helicobacter pylori* infection: a systematic review," *Obstetrics and Gynecology*, vol. 110, no. 3, pp. 695–703, 2007.

[45] I. Sandven, M. Abdelnoor, B. Nesheim, and K. K. Melby, "*Helicobacter pylori* infection and hyperemesis gravidarum: a systematic review and meta-analysis of case-control," *Acta Obstetricia et Gynecologica Scandinavica*, vol. 88, no. 11, pp. 1190–1200, 2009.

[46] M. N. Niemeijer, I. J. Grooten, N. Vos et al., "Diagnostic markers for hyperemesis gravidarum: a systematic review and metaanalysis," *American Journal of Obstetrics & Gynecology*, vol. 211, no. 2, pp. 150.e1–150.e15, 2014.
[63] C. M. El Younis, O. Abulafia, and D. M. Sherer, “Rapid marked response of severe hyperemesis gravidarum to oral erythromycin,” *The American Journal of Perinatology*, vol. 15, no. 9, pp. 533–534, 1998.

[64] O. Diav-Citrin, J. Arnon, S. Shechtman et al., “The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study,” *Alimentary Pharmacology and Therapeutics*, vol. 21, no. 3, pp. 269–275, 2005.